Global Novel Drug Delivery Systems In Cancer Therapy Market

Report ID : 1440 | Published : 2022-11-11 | Pages: | Format: PDF/EXCEL

The market size of the Global Novel Drug Delivery Systems In Cancer Therapy Market in the year 2021 is valued at 8.77 billion and is predicted to reach 50.45 billion by 2030 at an 21.75% CAGR during the forecast period.

High-end drug delivery methods include expressing plant and bioactive extracts in microcapsules, liposomes, nano emulsions, nano capsules, hydrogels, microspheres, nanoparticles, and polymeric materials. Due to significant advantages over conventional medicines for cancer treatment, the market for novel drug delivery systems in cancer therapy is expected to grow. An increase in cancer occurrences significantly impacts the global market for novel drug delivery systems in cancer therapy. Additionally, there has been increased research activity to create novel drug delivery systems and increased financing for ongoing research initiatives. The increase in the cost of healthcare for the detection and treatment of cancer is projected to contribute further to the expansion of the global market for novel drug delivery systems in cancer. Thus, with fresh investments and developments in the field, the high and rising burden of chronic diseases is anticipated to pave the way for developing novel drug delivery systems, and the studied market is thus expected to expand throughout the forecast period. Furthermore, the demand for novel drug delivery systems in cancer therapy is anticipated to increase due to technological developments in drug delivery systems, new investments made by private and public entities, new product launches, partnerships, and mergers and acquisitions by leading market players.

Market Segmentation:

The novel drug delivery systems in the cancer therapy market are segmented based on product. Based on the product, the market is segmented into nanoparticles (liposomes, polymer, micelles, other nanoparticles) and embolization particles (PVA particles, drug-eluting beads, liquid emboli, and other embolization particles).

Based on the product, the nanoparticles segment is a significant contributor to the novel drug delivery systems in the cancer therapy market.

The nanoparticles segment is estimated to hold the largest share of the market. An innovative strategy for treating cancer uses nanoparticles as new drug delivery mechanisms. They enclose the medications and guard them against enzymatic and chemical deterioration. Long circulation half-lives, fewer adverse effects, and improved pharmacokinetics are all benefits of using nanoparticles in medication administration. Additionally, these particles have improved permeability, enabling effective medication delivery to cancer tissues.

In the region, the North American novel drug delivery systems in the cancer therapy market hold a significant revenue share.

North America region is projected to hold the largest share in the market of novel drug delivery systems in cancer therapy globally. The market is projected that the existence of various manufacturers and the availability of research funding will promote market expansion in North America or future developments in the global market for novel drug delivery systems in cancer therapy.  The Asia Pacific regional market is expected to increase rapidly in the global novel drug delivery systems in cancer therapy due to the invention and introduction of technologically sophisticated drug delivery systems. Furthermore, the growing patient population with chronic diseases is predicted to propel market growth.

Competitive Landscape

 Some major key players in the Novel Drug Delivery Systems in Cancer Therapy market are Teva Pharmaceutical Industries Ltd.; Johnson & Johnson Services, Inc.; GALEN; Merrimack Pharmaceuticals, Inc.; Shire; Samyang Biopharmaceuticals Corporation; Celgene Corporation; Spectrum Pharmaceuticals, Inc.; BTG.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Novel Drug Delivery Systems in Cancer Therapy Market Snapshot

Chapter 4. Global Novel Drug Delivery Systems in Cancer Therapy Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis

5.1. by Product Type & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Product Type:

5.2.1. Nanoparticles

5.2.1.1. Liposomes

5.2.1.2. Polymer

5.2.1.3. Micelles

5.2.1.4. Other nanoparticles

5.2.2. Embolization particles

5.2.2.1. PVA particles

5.2.2.2. Drug-eluting beads

5.2.2.3. Liquid emboli

5.2.2.4. Other embolization particles

Chapter 6. Novel Drug Delivery Systems in Cancer Therapy Market Segmentation 2: Regional Estimates & Trend Analysis

6.1. North America

6.1.1. North America Novel Drug Delivery Systems in Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2030

6.1.2. North America Novel Drug Delivery Systems in Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2030

6.2. Europe

6.2.1. Europe Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2019-2030

6.2.2. Europe Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2019-2030

6.3. Asia Pacific

6.3.1. Asia Pacific Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2019-2030

6.3.2. Asia Pacific Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2019-2030

6.4. Latin America

6.4.1. Latin America Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2019-2030

6.4.2. Latin America Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2019-2030

6.5. Middle East & Africa

6.5.1. Middle East & Africa Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2019-2030

6.5.2. Middle East & Africa Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2019-2030

Chapter 7. Competitive Landscape

7.1. Major Mergers and Acquisitions/Strategic Alliances

7.2. Company Profiles

7.2.1. Teva Pharmaceutical Industries Ltd.

7.2.2. Johnson & Johnson Services, Inc.

7.2.3. GALEN; Merrimack Pharmaceuticals, Inc.

7.2.4. Shire

7.2.5. Samyang Biopharmaceuticals Corporation

7.2.6. Celgene Corporation

7.2.7. Spectrum Pharmaceuticals, Inc.

7.2.8. BTG

7.2.9. Other Prominent Players

By Product

  • Nanoparticles
    • Liposomes
    • Polymer
    • Micelles
    • Other nanoparticles
  • Embolization particles
    • PVA particles
    • Drug-eluting beads
    • Liquid emboli
    • Other Embolization particles

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients